| The tumor microenvironment in the response to immune checkpoint blockade therapies F Petitprez, M Meylan, A de Reyniès, C Sautès-Fridman, WH Fridman Frontiers in immunology 11, 533888, 2020 | 404 | 2020 |
| Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer M Meylan, F Petitprez, E Becht, A Bougoüin, G Pupier, A Calvez, I Giglioli, ... Immunity 55 (3), 527-541. e5, 2022 | 261 | 2022 |
| B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome WH Fridman, M Meylan, F Petitprez, CM Sun, A Italiano, ... Nature reviews Clinical oncology 19 (7), 441-457, 2022 | 207 | 2022 |
| B cells and cancer: To B or not to B? WH Fridman, F Petitprez, M Meylan, TWW Chen, CM Sun, LT Roumenina, ... Journal of Experimental Medicine 218 (1), e20200851, 2020 | 135 | 2020 |
| Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open … YA Vano, R Elaidi, M Bennamoun, C Chevreau, D Borchiellini, D Pannier, ... The Lancet Oncology 23 (5), 612-624, 2022 | 85 | 2022 |
| The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression F Petitprez, S Levy, CM Sun, M Meylan, C Linhard, E Becht, N Elarouci, ... Genome medicine 12, 1-15, 2020 | 80 | 2020 |
| Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions J Russick, PE Joubert, M Gillard-Bocquet, C Torset, M Meylan, F Petitprez, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 66 | 2020 |
| Early hepatic lesions display immature tertiary lymphoid structures and show elevated expression of immune inhibitory and immunosuppressive molecules M Meylan, F Petitprez, L Lacroix, L Di Tommaso, M Roncalli, A Bougoüin, ... Clinical Cancer Research 26 (16), 4381-4389, 2020 | 61 | 2020 |
| Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer C Sautes-Fridman, J Verneau, CM Sun, M Moreira, TWW Chen, M Meylan, ... Seminars in Immunology 48, 101406, 2020 | 58 | 2020 |
| Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade S Terry, C Dalban, N Rioux-Leclercq, J Adam, M Meylan, S Buart, ... Clinical Cancer Research 27 (24), 6749-6760, 2021 | 49 | 2021 |
| Complement C1s and C4d as prognostic biomarkers in renal cancer: emergence of noncanonical functions of C1s MV Daugan, M Revel, J Russick, MA Dragon-Durey, C Gaboriaud, ... Cancer Immunology Research 9 (8), 891-908, 2021 | 48 | 2021 |
| Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy K White, K Connor, M Meylan, A Bougoüin, M Salvucci, F Bielle, ... Annals of Oncology 34 (3), 300-314, 2023 | 34 | 2023 |
| An eight-gene hypoxia signature predicts survival in pancreatic cancer and is associated with an immunosuppressed tumor microenvironment R Abou Khouzam, SP Rao, GH Venkatesh, NA Zeinelabdin, S Buart, ... Frontiers in immunology 12, 680435, 2021 | 34 | 2021 |
| Tertiary lymphoid structures and B cells: An intratumoral immunity cycle WH Fridman, M Meylan, G Pupier, A Calvez, I Hernandez, ... Immunity, 2023 | 28 | 2023 |
| Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated … L Carril-Ajuria, A Desnoyer, M Meylan, C Dalban, M Naigeon, L Cassard, ... Journal for Immunotherapy of Cancer 10 (5), 2022 | 18 | 2022 |
| Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity MA Dragon-Durey, X Chen, A Kirilovsky, N Ben Hamouda, C El Sissy, ... PLoS One 16 (5), e0252026, 2021 | 15 | 2021 |
| 700O kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N) M Meylan, B Beuselinck, C Dalban, Y Vano, NR Leclercq, ... Annals of Oncology 31, S553, 2020 | 10 | 2020 |
| The tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020; 11: 784 F Petitprez, M Meylan, A de Reyniès, C Sautès-Fridman, WH Fridman | 10 | 2020 |
| Immune signature linked to COVID-19 severity: A SARS-score for personalized medicine J Russick, PE Foy, N Josseaume, M Meylan, NB Hamouda, A Kirilovsky, ... Frontiers in Immunology 12, 701273, 2021 | 4 | 2021 |
| webMCP-counter: a web interface for transcriptomics-based quantification of immune and stromal cells in heterogeneous human or murine samples M Meylan, E Becht, C Sautès-Fridman, A de Reyniès, WH Fridman, ... BioRxiv, 2020.12. 03.400754, 2020 | 4 | 2020 |
catherine sautès-fridmanUniversity of ParisVerified email at crc.jussieu.fr
